AUTL
NASDAQAutolus Therapeutics plc
Price$1.53-0.10 (-6.13%)
2026-03-042026-06-05
News · 26 weeks59-83%
2025-12-142026-06-07
Mix4590d
- Insider21(47%)
- SEC Filings10(22%)
- Other10(22%)
- Earnings4(9%)
Latest news
25 items- PRAutolus Therapeutics to Participate in Upcoming Investor ConferencesLONDON and GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will present and host meetings at two upcoming investor conferences. William Blair's 46th Annual Growth Stock ConferenceDate and time: June 2, 2026; 1:20pm CDT / 7:20pm BSTLocation: Chicago, ILPresenter: Chief Executive Officer Dr. Christian Itin Jefferies Global Healthcare ConferenceDate and time: June 3, 2026; 10:30am EDT / 3:30pm BSTLocation: New York, NYPresenter: Chief Executive Officer Dr. Christian Itin Webcasts of the pres
- PRAutolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois. "Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival compared to marrow-only relapse. With
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Autolus Therapeutics plcSCHEDULE 13G/A - Autolus Therapeutics plc (0001730463) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Autolus Therapeutics plcSCHEDULE 13G/A - Autolus Therapeutics plc (0001730463) (Subject)
- SECSEC Form 10-Q filed by Autolus Therapeutics plc10-Q - Autolus Therapeutics plc (0001730463) (Filer)
- SECAutolus Therapeutics plc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Autolus Therapeutics plc (0001730463) (Filer)
- PRAutolus Therapeutics Reports First Quarter 2026 Financial Results and Business UpdatesAUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $26.2 million for the first quarter of 2026, reflecting strong launches in the US and most recently the UKCompany achieves positive gross margin for the acute lymphoblastic leukemia (ALL) business Cost reduction initiative to drive gross profit margin improvement and path to profitability for the ALL business underwayObe-cel clinical development programs on track with trial enrollment ongoing in lupus nephritis, pediatric ALL and progressive multiple sclerosis (MS)Conference call to be held today at 8:30am EDT/1:30pm BST: conference call participants should pre-register using the link at the bottom of this press release LON
- SECSEC Form EFFECT filed by Autolus Therapeutics plcEFFECT - Autolus Therapeutics plc (0001730463) (Filer)
- SECSEC Form EFFECT filed by Autolus Therapeutics plcEFFECT - Autolus Therapeutics plc (0001730463) (Filer)
- PRAutolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026LONDON and GAITHERSBURG, Md., May 05, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that the Company will release its first quarter 2026 financial results and operational highlights before open of U.S. markets on Thursday, May 14, 2026. Management will host a conference call and webcast at 8:30am EDT / 1:30pm BST to discuss the company's financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required
- SECAutolus Therapeutics plc filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure8-K - Autolus Therapeutics plc (0001730463) (Filer)
- PRAutolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost ReductionInitiative focused on driving gross profit margin and path to profitability for the ALL businessCompany will reduce headcount by approximately 13% while doubling manufacturing of products for commercial and clinical trial patients in 2026 Autolus reiterates full year 2026 AUCATZYL® net product revenue of $120 million to $135 million, up from $74 million in 2025, as well as an anticipated shift to positive gross margin in 2026Clinical development programs are on track and include CATULUS, a pivotal Phase 2 trial in pediatric relapsed/refractory acute lymphoblastic leukemia; LUMINA, a pivotal Phase 2 trial in lupus nephritis; and BOBCAT, an exploratory Phase 1 trial in progressive multiple scl
- PRAdvancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial RecognitionAUSTIN, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: The biotechnology industry is experiencing a subtle yet meaningful transformation that is redefining how value is interpreted within a sector long associated with extended development cycles and inherent uncertainty. As therapeutic candidates advance toward commercialization, scientific achievement is no longer viewed purely as an expense tied to research and development but rather as something that can be quantified as a financial asset. This transition is supported by fair-value accounting principles under U.S. GAAP, which enable life sciences companies to incorporate clinical progress, probability of succes
- PRAutolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)LONDON and GAITHERSBURG, Md., April 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Compensation Committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 68,500 American Depositary Shares and 57,765 restricted stock units (RSUs), each representing an equal number of ordinary shares, to 15 employees pursuant to the Company's 2025 Inducement Plan. The stock options and RSUs were granted as an inducement material to the individual becoming an employee of Autol
- SECAutolus Therapeutics plc filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits8-K - Autolus Therapeutics plc (0001730463) (Filer)
- SECSEC Form DEL AM filed by Autolus Therapeutics plcDEL AM - Autolus Therapeutics plc (0001730463) (Filer)
- SECSEC Form DEL AM filed by Autolus Therapeutics plcDEL AM - Autolus Therapeutics plc (0001730463) (Filer)
- SECSEC Form S-3 filed by Autolus Therapeutics plcS-3 - Autolus Therapeutics plc (0001730463) (Filer)
- SECAutolus Therapeutics plc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Autolus Therapeutics plc (0001730463) (Filer)
- PRAutolus Therapeutics to Participate in Upcoming Investor ConferencesLONDON and GAITHERSBURG, Md., April 07, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announced that the Company will participate in two upcoming investor conferences. 25th Annual Needham Virtual Healthcare ConferenceDate and time: April 13, 2028; 10:15am EDT / 3:15pm BSTPresenter: Chief Executive Officer Dr. Christian Itin A webcast of the presentation will be available on the "Events" page in the "Investor Relations & Media" section of the Company's website at https://www.autolus.com/investor-relations-media/events/. A replay of the webca
- SECSEC Form 10-K filed by Autolus Therapeutics plc10-K - Autolus Therapeutics plc (0001730463) (Filer)
- SECAutolus Therapeutics plc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Autolus Therapeutics plc (0001730463) (Filer)
- PRAutolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business UpdatesAUCATZYL® (obecabtagene autoleucel) net product revenue of $23.3 million* for the fourth quarter of 2025 and $74.3 million* for the full year of 2025AUCATZYL® UK launch underway following successful National Institute for Health and Care Excellence (NICE) evaluationAutolus continues to expect full year 2026 AUCATZYL® net product revenue of $120 million to $135 million and shift to positive gross margin to occur in 2026Independent real-world AUCATZYL® data from ROCCA consortium confirm high level of clinical activity with favorable safety profile Pivotal Phase 2 clinical trials with obe-cel in lupus nephritis and pediatric ALL enrolling; initial clinical data from BOBCAT Phase 1 trial in pro
- INSIDERSEC Form 3 filed by new insider Richardson Ryan3 - Autolus Therapeutics plc (0001730463) (Issuer)
- INSIDERSEC Form 3 filed by new insider Piccina Cintia3 - Autolus Therapeutics plc (0001730463) (Issuer)
AUTL FAQ
7 questionsWhat does Autolus Therapeutics plc do?
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer. Autolus Therapeutics plc was founded in 2014 and is...Where does AUTL stock trade?
Autolus Therapeutics plc (AUTL) is listed on NASDAQ.What sector and industry is AUTL in?
Autolus Therapeutics plc operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Autolus Therapeutics plc go public?
Autolus Therapeutics plc (AUTL) completed its IPO in 2018.What are analysts saying about AUTL?
Autolus Therapeutics plc has had 6 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $900.00 price target on 2026-02-17. Recent price targets range from $500.00 to $1300.00.What companies are similar to AUTL?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare AUTL side-by-side with any of them on Quantisnow.How can I track AUTL on Quantisnow?
Quantisnow aggregates Autolus Therapeutics plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AUTL to receive live email and push alerts on every new disclosure.